Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country

• Published in: BMC infectious diseases 2023-02, Vol.23 (1), p.106-106, Article 106
• Main Authors: Joudeh, Nagham, Sawafta, Elana, Abu Taha, Adham, Hamed Allah, Majd, Amer, Riad, Odeh, Razan Y, Salameh, Husam, Sabateen, Ali, Aiesh, Banan M, Zyoud, Sa'ed H
• Format: Article
• Language: English
• Subjects: Acute lymphoblastic leukemia; Acute myeloid leukemia; Acyclovir; Adult; Amikacin; Ampicillin; Anti-Bacterial Agents - therapeutic use; Antibacterial agents; Antibiotics; Antimicrobial agents; Antimicrobial resistance; Bacteria; Bacterial infections; Cancer; Cancer patients; Cancer therapies; Care and treatment; Catheters; Ceftazidime; Cell culture; Cellulitis; Chemotherapy; Colitis; Cytotoxicity; Data collection; Dehydrogenases; Developing Countries; Dosage and administration; Drug resistance; Epidemiology; Febrile neutropenia; Febrile Neutropenia - complications; Febrile Neutropenia - drug therapy; Female; Fever; Fever - etiology; Fluconazole; Fungal infections; Gram-positive bacteria; Hematologic Neoplasms - complications; Hospitals; Humans; Klebsiella; Klebsiella pneumoniae; LDCs; Leukemia; Leukemia, Myeloid, Acute - complications; Levofloxacin; Lymphatic leukemia; Lymphoma; Male; Malignancy; Methods; Middle Aged; Mortality; Multidrug resistant organisms; Neutropenia; Neutrophils; Pathogens; Patient outcomes; Patients; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Prevention; Retrospective Studies; Risk factors; Staphylococcus infections; Tazobactam; Vancomycin
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-023-08058-6

Febrile neutropenia (FN) is a life-threatening complication that predisposes cancer patients to serious infections. This study aims to describe the epidemiology and source of infection in cancer patients with FN in a tertiary care hospital. A hospital-based retrospective study was conducted in a large tertiary care hospital from January 2020 to December 2021. Data on cancer patients with FN were collected from the hospital information system. 150 cancer patients with FN were identified during the study period. Most patients were males (98; 65.3%), and the mean age of participants was 42.2 ± 16.0 years. Most patients (127; 84.7%) had hematologic malignancies, and acute myeloid leukemia was the most common diagnosis (42; 28%), followed by acute lymphocytic leukemia (28; 18.7%) and Hodgkin's lymphoma (20; 13.3%). Fifty-four (36%) patients had a median Multinational Association for Supportive Care in Cancer (MASCC) scores greater than 21. Regarding the outcome, nine (6%) died, and 141(94%) were discharged. The focus of fever was unknown in most patients (108; 72%). Among the known origins of fever were colitis (12; 8%), pneumonia (8; 5.3%), cellulitis (6; 4%), bloodstream infections (7; 4.6%), perianal abscess (2; 1.3%) and others. The median duration of fever was two days, and the median duration of neutropenia was seven days. Sixty-three (42%) patients had infections: 56 (73.3%) were bacterial, four (2.6%) were viral, two (1%) were fungal and 1 (0.7%) was parasitic. Among the bacterial causes, 50 cases (89.2%) were culture-positive. Among the culture-positive cases, 34 (68%) were gram-positive and 22 (44%) were gram-negative. The most frequent gram-positive bacteria were E. faecalis (9; 18% of culture-positive cases), and the most frequent gram-negative organisms were Klebsiella pneumoniae (5; 10%). Levofloxacin was the most commonly used prophylactic antibiotic (23; 15.33%), followed by acyclovir (1610.7%) and fluconazole in 15 patients (10%). Amikacin was the most popular empiric therapy, followed by piperacillin/tazobactam (74; 49.3%), ceftazidime (70; 46.7%), and vancomycin (63; 42%). One-third of E. faecalis isolates were resistant to ampicillin. Approximately two-thirds of Klebsiella pneumoniae isolates were resistant to piperacillin/tazobactam and ceftazidime. Amikacin resistance was proven in 20% of isolates. The majority of patients suffered from hematologic malignancies. Less than half of the patients had infections, and the majority were bacterial